玻璃体内注射阿柏西普治疗糖尿病性黄斑水肿的效果观察  

Observation on the efficacy of intravitreal injection of aflibercept for the treatment of diabetic macular edema

作　　者：贾晓鑫 李兵 Jia Xiaoxin;Li Bing(Nanyang Eye Hospital,Henan 473000,China)

机构地区：[1]南阳市眼科医院,河南473000

出　　处：《中华眼外伤职业眼病杂志》2021年第9期690-693,共4页Chinese Journal of Ocular Trauma and Occupational Eye Disease

摘　　要：目的观察玻璃体内注射阿柏西普治疗糖尿病性黄斑水肿(DME)的效果。方法回顾性分析2018年8月至2020年4月南阳市眼科医院玻璃体内注射阿柏西普24例(31眼)DME的临床资料。观察注射前、注射后3个月、6个月的视力及黄斑中心区厚度(CMT)。随访(7.2±1.5)个月。结果注药前视力(BCVA,log MAR)为0.83±0.21,术后3个月提高至0.45±0.13(t=8.642,P<0.001)。术后6个月视力为0.61±0.17,仍优于术前(t=5.003,P=0.001)。CMT术前平均为(385.62±112.76)μm,术后3个月降至(213.81±79.13)μm(t=7.043,P<0.001),术后6个月为(273.67±93.25)μm,仍优于术前(t=4.589,P=0.001)。结论玻璃体内注射阿柏西普可以减轻糖尿病性黄斑水肿病变程度,提高视力。Objective To observe the efficacy of intravitreal injection of aflibercept for the treatment of diabetic macular edema(DME).Methods The clinical data of 31 eyes of 24 patients with DME from Aug.2018 to Apr.2020 in Nanyang Eye Hospital were analyzed retrospectively.All cases received intravitreal injection of aflibercept.The visual acuity and central macular thickness(CMT)were observed before injection and 3 and 6 months after injection.The follow-up time was(7.2±1.5)months.Results The vision(BCVA,log MAR)was 0.83±0.21 before injection,which improved to 0.45±0.13 at 3 months after injection(t=8.642,P<0.001).The visual acuity at 6 months after operation was 0.61±0.17,which was also better than that before operation(t=5.003,P=0.001).The mean CMT was(385.62±112.76)μm before operation,which decreased to(213.81±79.13)μm at 3 months after operation(t=7.043,P<0.001),and the CMT was(273.67±93.25)μm at 6 months after operation,which was still better than that before operation(t=4.589,P=0.001).Conclusion Intravitreal injection of aflibercept can reduce the degree of diabetic macular edema and improve visual acuity.

关 键 词：水肿 黄斑 糖尿病性 阿柏西普 注射 玻璃体内 效果 治疗 

分 类 号：R587.2[医药卫生—内分泌] R774.5[医药卫生—内科学]